We have located links that may give you full text access.
CLINICAL TRIAL
COMPARATIVE STUDY
JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy.
Clinical Endocrinology 1994 November
OBJECTIVE: Hypercalcaemia of malignancy (HM) is a common metabolic complication associated with cancer. The hypocalcaemic effects of medications used to reduce serum calcium levels in HM are short lived and relapse in hypercalcaemia is not uncommon. Pamidronate is one of the most commonly used bisphosphonates in the treatment of HM but there are no specific guidelines for the frequency of use of this drug in recurrent hypercalcaemia. This study was conducted to assess the optimum frequency of pamidronate therapy necessary to maintain normocalcaemia in patients with HM.
DESIGN AND PATIENTS: Thirty-four patients with HM were randomly allocated into two groups and treated with intravenous pamidronate administered every 14th or 21st day for 16 weeks (n = 17 each group). Serum calcium and urinary hydroxyproline creatinine ratio were measured at weekly intervals.
RESULTS: The calcium-lowering effect of pamidronate was apparent by 48 hours and normocalcaemia was maintained for an average of 15 days. When the drug was administered every 3 weeks, hypercalcaemia and associated symptoms developed in 50% of patients (22 separate episodes) during the 3rd week, before the next dose of pamidronate. The incidence of symptomatic hypercalcaemia was significantly decreased (10%, 8 separate episodes, P < 0.01) and survival was improved (P < 0.05) in patients who received pamidronate every 2nd week, thereby minimizing the unpleasant and potentially dangerous effects of hypercalcaemia.
CONCLUSIONS: Intravenous pamidronate 60 mg/dose, administered every two weeks, can maintain normocalcaemia in the vast majority of patients with hypercalcaemia of malignancy.
DESIGN AND PATIENTS: Thirty-four patients with HM were randomly allocated into two groups and treated with intravenous pamidronate administered every 14th or 21st day for 16 weeks (n = 17 each group). Serum calcium and urinary hydroxyproline creatinine ratio were measured at weekly intervals.
RESULTS: The calcium-lowering effect of pamidronate was apparent by 48 hours and normocalcaemia was maintained for an average of 15 days. When the drug was administered every 3 weeks, hypercalcaemia and associated symptoms developed in 50% of patients (22 separate episodes) during the 3rd week, before the next dose of pamidronate. The incidence of symptomatic hypercalcaemia was significantly decreased (10%, 8 separate episodes, P < 0.01) and survival was improved (P < 0.05) in patients who received pamidronate every 2nd week, thereby minimizing the unpleasant and potentially dangerous effects of hypercalcaemia.
CONCLUSIONS: Intravenous pamidronate 60 mg/dose, administered every two weeks, can maintain normocalcaemia in the vast majority of patients with hypercalcaemia of malignancy.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app